Halozyme announces $1.05B convertible notes offering due 2033

HALOZYME THERAPEUTICS, INC.

Offering of $1.05B aggregate principal of convertible senior notes due 2033, unsecured, semi-annual interest, maturing Oct 1, 2033.
13-day option for initial purchasers to buy up to $150M additional notes, for potential total of $1.2B.
Proceeds to fund capped call transactions, repurchase existing 0.25% 2027 and 1.00% 2028 convertible notes, and general corporate purposes.
Capped calls intended to reduce dilution; concurrent note repurchases may affect common stock price.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.